METiS TechBio (7666.HK), a leading AI-powered drug delivery innovation company, and WestVac Biopharma, an innovative vaccine and immunotherapy company led by Professor Yuquan Wei, Academician of the Chinese Academy of Sciences, have officially signed a strategic cooperation framework agreement. Leveraging METiS TechBio’s proprietary AI-driven nano-delivery platform NanoForge and WestVac Biopharma’s vaccine R&D and industrialization platform, the two parties will accelerate the AI-driven development of next-generation personalized mRNA cancer vaccines and advance related technological innovation and clinical translation.
Under the agreement, the two parties will combine NanoForge’s end-to-end Biological AI capabilities with WestVac Biopharma’s vaccine R&D and industrialization platform to jointly explore AI-enabled applications in personalized antigen screening, design and delivery, accelerating innovation and clinical translation of next-generation personalized mRNA cancer vaccines. METiS TechBio will contribute core technological capabilities under the NanoForge platform, including AiLNP and AiRNA, while WestVac Biopharma will contribute its industrialization expertise in antigen design, vaccine manufacturing processes and clinical development.
WestVac Biopharma was founded in July 2020 by a team of scientists led by Professor Yuquan Wei, Academician of the Chinese Academy of Sciences and Director of the National Key Laboratory of Biotherapy at West China Hospital, Sichuan University. The company has advanced biomanufacturing platforms, including Asia’s only insect cell expression platform with full industrialization capabilities. It has established five major technology platforms: a mature insect cell expression platform, an mRNA vaccine platform, a novel adjuvant platform, a bacterial vaccine platform, and a tumor vaccine and immunotherapy platform. Its product pipeline covers COVID-19 vaccines, influenza vaccines, tumor vaccines and other areas. Its recombinant COVID-19 vaccine, Coviccine® Trivalent XBB Vaccine, was the world’s first COVID-19 vaccine targeting XBB and other variants to receive emergency use approval.
Dr. Chris Lai, Co-founder, Chairman and Chief Executive Officer of METiS TechBio, said: “Personalized mRNA cancer vaccines represent one of the ultimate applications of AI-driven precision immunotherapy. Each patient has a distinct tumor mutation profile, requiring AI to complete neoantigen prediction, mRNA sequence design and delivery system matching within days. METiS TechBio’s NanoForge platform integrates the mRNA sequence design capabilities of AiRNA with the targeted LNP delivery capabilities of AiLNP. We have achieved targeted delivery across eight major human organs and tissues, enabling an end-to-end closed-loop R&D workflow from antigen design to delivery validation across different tumor types. WestVac Biopharma, led by Academician Wei, has world-class capabilities in vaccine clinical development and industrialization. We look forward to combining our strengths to deeply integrate AI-driven personalized antigen prediction with targeted delivery and accelerate innovation in personalized mRNA cancer vaccines.”
About WestVac Biopharma
WestVac Biopharma is a national high-tech enterprise driven by cutting-edge biotechnology. Founded by the team of Academician Yuquan Wei from the National Key Laboratory of Biotherapy at West China Hospital, Sichuan University, the company focuses on the prevention and treatment of respiratory infectious diseases and integrates the R&D, manufacturing and commercialization of innovative vaccines and biologics. WestVac Biopharma currently operates advanced biomanufacturing platforms, including Asia’s only insect cell expression platform with full industrialization capabilities.
About METiS TechBio
METiS TechBio (Stock Code: 7666.HK) is an AI-driven TechBio company co-founded in 2020 by Dr. Hongming Chen, a Member of the U.S. National Academy of Engineering, and MIT scientists Dr. Chris Lai and Dr. Wenshou Wang. On May 13, 2026, the Company was successfully listed on the Hong Kong Stock Exchange, becoming the world’s first publicly listed AI-powered drug delivery company.
Through its proprietary Biological AI foundation platform NanoForge, METiS TechBio integrates AI foundation models, METiS AI Agents, quantum chemistry and molecular dynamics simulations, high-throughput experimentation, and proprietary dry- and wet-lab data, with the goal of enabling the targeted delivery and application of payloads across life forms. Through its dual-engine “platform + product” business model, the Company continues to extend AI from molecular design into more complex life science systems, building a Biological AI life science technology platform with sustained capabilities in scientific innovation and translation.
The Company has developed precision targeted delivery capabilities across eight key organs and tissues, including the liver, lungs, muscles and immune cells, achieving breakthroughs in multi-organ and multi-tissue targeted delivery. These capabilities create opportunities for drug development across oncology, metabolic diseases, autoimmune diseases and neurodegenerative diseases, while also opening up possibilities for anti-aging interventions at the organ level.
